P E

Presse Ethypharm

Press

chez Ethypharm

Contacter

Ethypharm Group

Ethypharm is a European pharmaceutical company focused on two areas: the Central Nervous System and Hospital injectables. Ethypharm markets its drugs directly in Europe and China, and with partners in North America and the Middle East where its drugs are in high demand. The Group employs 1,750 people, mainly in Europe and China. Ethypharm works closely with authorities and healthcare professionals to ensure the appropriate use of and access to its medicines, by as many people as possible.

23/04/2021

Health

Ethypharm establishes direct presence in Italy

Ethypharm announces today that it now has a fully established affiliate to operate directly in Italy, the third largest pharmaceutical market in Europe. Under the leadership of Bruno Rago, Ethypharm Italy will reinforce the group's commercial footprint in Europe, notably in its core therapeutic area of the Central Nervous System. Founded in 1977 in France, Ethypharm is a specialty pharmaceutical company with solid roots in Europe and China. After its establishment in the United Kingdom and Germany in 2015, the addition of a direct presence in Italy is a major milestone to strengthen the group’s commercial platform in Europe. Ethypharm Italy Srl is headquartered in Padova and will serve both the hospital and retail pharmacy channels.  Ethypharm Italy does not start from scratch but builds on solid foundations. Ethypharm already had several of its products distributed in Italy, notably in the Central Nervous System area. The team in place reflects the human values of Ethypharm: entrepreneurial spirit, strong pharmaceutical expertise and unique commitment to improve the life of patients. “Bruno Rago is a senior pharma and biotech industry executive. With him, Ethypharm benefits from over 20 years of experience. Bruno has a passion for building and establishing pharmaceutical affiliates in Italy and Europe. We know that under his leadership, Ethypharm Italy has a bright future” says Jean Monin, Chief Commercial Operations Officer of Ethypharm. Italy is one of the world's leading pharmaceutical markets. In 2019, the pharmaceutical market in Italy was estimated at 30 billion euros1]. Within it, the off-patent CNS market was worth 3,4 billlion euros. “I am happy to take this new challenge and I am confident as I already know the potential and the value of Ethypharm’s strategy and portfolio. I also know that we are able to relieve patients in pathologies such as epilepsy, pain and depression where healthcare professionnals and patients have needs” explains Bruno Rago, general manager of Ethypharm Italy.  About Ethypharm Ethypharm is a European pharmaceutical company focused on two therapeutic areas: the Central Nervous System and Critical Care. Ethypharm markets its drugs directly in Europe and China, and with partners in North America and the Middle East where its drugs are in high demand. The Group employs more than 1,500 people, mainly in Europe and China. Ethypharm works closely with authorities and healthcare professionals to ensure the appropriate use of and access to its medicines, by as many people as possible. For more information visit www.ethypharm.com and follow us on LinkedIn Media Contacts Ethypharm: Mai Tran, presse@ethypharm.com, + 33 (0)6 64 74 70 80

Lire la suite

06/04/2021

Health

Ethypharm ready to bring to patients world-leading digital therapies for depression and addiction

Saint-Cloud, France – April 6th, 2021 – Ethypharm announces today that it has acquired exclusive rights for two CE-marked digital therapies, deprexis® and vorvida®, developed by GAIA AG (GAIA), a global leader in digital therapeutics. With these innovative clinically-proven digital therapies, Ethypharm strengthens its product offering to support patients and healthcare providers in its core area of the Central Nervous System (CNS) where there are significant unmet needs. 30 million European individuals suffer from depression. The burden of mental disorders is growing, with significant impacts on health and major social and economic consequences. The ongoing COVID-19 pandemic is leading to an increase in cases of depression and alcohol use disorders (AUD). In parallel, to address the pandemic, digital health technologies have been adopted at a fast pace to help maintain an appropriate care of patients. In this context and using its expertise in CNS, and more specifically in pain, addiction and depression, Ethypharm has identified that, beyond conventional medicines, innovative and reliable therapeutic solutions could offer new alternatives to treat patients and support healthcare professionals currently facing unmet needs. deprexis® is a web-based digital therapy medical device to help patients manage their symptoms of depression and one of the world’s most researched digital treatments. vorvida® is helping to reduce the risks and damages caused by problematic alcohol consumption. This digital therapy has proven clinical efficacy in the treatment of bothersome or harmful alcohol consumption including diagnosed alcohol use disorder (AUD). Ethypharm acquires exclusive rights for deprexis® in 4 European countries: France, the United Kingdom, Italy and Spain. vorvida® is first licenced for France, with rights to future extensions in other European countries. Under the terms of the agreement with GAIA, Ethypharm will ensure the marketing and sales of these two digital therapeutics within their licenced territories. Digital therapeutics will be a key lever to Ethypharm’s growth. According to Market Data Forecast, the European digital therapeutics market was valued at US$ 612 million in 2020 and is forecasted to grow at a compounded annual growth rate of 21.4% between 2021 to 2026. “Mental disorders are a worldwide major burden on people, society and the economy. With COVID-19 and associated growing concerns on mental health, we wanted to provide innovative treatment options for patients and their physicians. These disruptive digital therapies have proven their efficacy and therefore, fit extremely well with Ethypharm’s ambition to improve people’s lives. The partnership with GAIA, a pioneer in digital health, is the illustration of the ability of Ethypharm to listen to unmet needs and either to develop or find the optimal partner to answer them.” said Bertrand Deluard, CEO of Ethypharm. "After 20 years of R&D in this field, it is great to see that healthcare systems all over Europe start realising the enormous potential that scientifically proven DTx products have to offer. We are therefore more than happy that Ethypharm will bring two of our products to key European markets, helping to reduce the enormous medical, psychological and economical burden these diseases create. " Dr. Mario Weiss, CEO and Founder of GAIA, commented. About Ethypharm Ethypharm is a European pharmaceutical company focused on two therapeutic areas: the Central Nervous System and Critical Care. Ethypharm markets its drugs directly in Europe and China, and with partners in North America and the Middle East where its drugs are in high demand. The Group employs more than 1,500 people, mainly in Europe and China. Ethypharm works closely with authorities and healthcare professionals to ensure the appropriate use of and access to its medicines, by as many people as possible. For more information visit www.ethypharm.com and follow us on LinkedIn About GAIA GAIA is a global leader in digital therapeutics (DTx), launching its first product successfully in 2001. With its stringent focus on research and development of evidence based, fully-automated online interventions the company continuously shifts benchmarks when it comes to effect sizes and safety profiles for digital therapeutics in neuroscience, immunology, oncology, or behavioral health. With more than 250 experts in the field of Medicine, Psychology, Behavioral Medicine, Software Engineering as well as Regulatory and Market Access, GAIA is one of the most experienced and largest global players in the development of next generation digital solutions to support and treat patients with a broad variety of medical conditions. For more information about GAIA please visit www.gaia-group.com. You can also follow GAIA on Twitter, @GAIA_COM, and LinkedIn Media Contacts • Ethypharm: Mai Tran, presse@ethypharm.com, + 33 (0)6 64 74 70 80 • GAIA: Johann Meyer-Christian, johann.meyerchristian@gaia-group.com, +41 79 614 46 44

Lire la suite

16/03/2021

Health

Ethypharm partners with Clever Leaves for medical cannabis products in Germany

St-Cloud, France – March 17th, 2021 – Ethypharm has signed an exclusive licence agreement with Clever Leaves for the sale of medical cannabis extracts in Germany, the most important European market for medical cannabis. For Ethypharm, this is a further step to become a leading and trusted provider of medical cannabis products in Europe. This agreement expands the Ethypharm Group’s offering in its core therapeutic area of the Central Nervous System and confirms its commitment to support patients suffering with chronic pain. “Working with physicians and pharmacists to improve people’s lives is one of Ethypharm’s daily ambitions. Today, providing medical cannabis will answer a clear unmet medical need for patients who are not relieved with current treatments. Partnerships are part of Ethypharm’s DNA. We always look for the optimal partner in any country or region of the world. This collaboration on medical cannabis with Clever Leaves is a good example of how Ethypharm has developed new ways to provide patients with the medical treatment care they need.” said Bertrand Deluard, CEO of Ethypharm. Clever Leaves, a well recognised cannabis company, will manufacture and supply EU-GMP certified medical cannabis extracts sourced from their facilities in Colombia. The finished products will be marketed and distributed as an Ethypharm branded product portfolio in Germany by its local subsidiary in the 2nd half of 2021. The portfolio include high-CBD, high-THC, and balanced CBD-THC formulations aiming at the symptomatic treatment of neurological diseases as well as chronic pain in palliative settings. “This partnership with Ethypharm, an established European pharmaceutical company, advances our goal of providing market-leading medical cannabis products to patients. Clever Leaves’ focus on high-quality EU-GMP production and international supply chain has positioned us to develop, produce and ship products to endmarkets that will have significant impact on patients’ treatments”, said Kyle Detwiler, CEO of Clever Leaves. Germany is the second European market after France where the Ethypharm Group offers medical cannabis. Last January, Ethypharm was selected by the French health agency (National Agency for the Safety of Medicines and Health Products - ANSM) to provide medical cannabis products for the first ever French medical cannabis pilot program. About the Ethypharm Group Ethypharm is a European pharmaceutical company focused on two therapeutic areas: the Central Nervous System and Critical Care. Ethypharm markets its drugs directly in Europe and China, and with partners in North America and the Middle East where its drugs are in high demand. The Group employs more than 1,500 people, mainly in Europe and China. Ethypharm works closely with authorities and healthcare professionals to ensure the appropriate use of and access to its medicines, by as many people as possible. For more information visit www.ethypharm.com and follow us on LinkedIn Media Contacts Ethypharm Corporate o Avril Ponnelle, presse@ethypharm.com, + 33 (0)1 41 12 17 20 Germany o Markus Gladbach, presse@thecommsduo.com, +49 157 71 44 60 98 o Christine Vogl-Kordick, presse@thecommsduo.com, +49 172 86 50 982

Lire la suite

26/01/2021

Health

Aurora Europe and Ethypharm collaborate to bring Medical Cannabis to French patients

Aurora Europe and Ethypharm selected to supply medical cannabis in the first ever French medical cannabis pilot program two-year program scheduled to commence by 31 March 2021 Berlin, Germany and St-Cloud, France, 26 January 2021 – Aurora Europe and the Ethypharm Group announce that they have reached a first important milestone in their collaboration agreement aimed at granting access to high-quality and trustworthy medical cannabis produced under European Good Manufacturing Practices (EU GMP) standard to patients and healthcare professionals in France. They are amongst the six producer and distributor tandems selected by the French health agency (National Agency for the Safety of Medicines and Health Products ANSM]) to provide medical cannabis products in the soon-to-start French pilot program. In a decree dated 7 October 2020, French authorities set the framework for a two-year pilot program of medical cannabis in France planned to start by 31 March 2021 and the French health agency ANSM was charged with running a tender process to select the medical cannabis products to be supplied in this program. Aurora Europe and the Ethypharm Group are happy to announce that they have been selected as the primary supplier for three lots out of nine awarded, which are: Aurora 20/1 (FR) (high-THC dried flowers), Aurora 8/8 (FR) (THC:CBD balanced dried flowers) and Aurora 1/12 (FR) (high-CBD dried flowers). With that the entire supply of dried flower medical cannabis to French patients during the pilot program will be ensured by this collaboration. “This is an important milestone and a great success for Aurora in our effort to improve the status and accessibility of medical cannabis in Europe,” said Dr. Axel GILLE, President of Aurora Europe. “Providing high-quality medical cannabis dried flower to the French pilot program is the first and very important step towards providing better access and will support the destigmatization of medical cannabis in France. If successful, this pilot program could lead to a regulated market for medical cannabis, which would be one of the largest in Europe.” Aurora has a proven track record of supporting the advancement of international medical cannabis markets alongside government bodies and with a deep commitment to compliance. This practice has led to successful leadership in expanding markets including Germany, Denmark, Poland and more recently Israel. “We are very proud to be part of the solution for patients seeking medical cannabis treatment. With our deep expertise in disorders of the Central Nervous System and in highly regulated medicines, we are well prepared to enter this new segment,” explained Bertrand DELUARD, President and CEO of Ethypharm. “Collaboration and partnerships are part of Ethypharm’s DNA. Combining our skills with Aurora’s pharmaceutical-quality cannabis products is in our view the right approach to build trust and confidence in medical cannabis for the long term.” Aurora and Ethypharm signed a collaboration agreement to serve the French pilot program in October 2020 leveraging both parties' expertise. Under the terms of the exclusive partnership, Aurora will supply European Good Manufacturing Practices (EU GMP) certified medical cannabis sourced directly from Aurora’s largest greenhouse production on European soil, Aurora Nordic, in Odense, Denmark, as well as manufacturing and logistics support. Laboratoires Ethypharm will be responsible for distribution and pharmacovigilance activities in France. About Aurora Europe Aurora Europe, headquartered in Berlin, Germany, is a subsidiary of Aurora Cannabis Inc., a global leader in the cannabis industry serving both medical and consumer markets and dedicated to helping people improve their lives. Aurora Europe supplies high-quality medical cannabis products to patients throughout Europe. In 2015, Aurora entered the German market and today operates one of the largest authorised importers and distributors of medical cannabis in Europe. Aurora’s internal network of EU GMP facilities continues to bring high-quality, premium medical cannabis to patients worldwide. For more information visit www.auroramedicine.com and follow us on LinkedIn. About the Ethypharm Group Ethypharm is a European pharmaceutical company focused on two therapeutic areas: the Central Nervous System and Critical Care. Ethypharm markets its drugs directly in Europe and China, and with partners in North America and the Middle East where its drugs are in high demand. The Group employs more than 1,500 people, mainly in Europe and China. Ethypharm works closely with authorities and healthcare professionals to ensure the appropriate use of and access to its medicines, by as many people as possible. For more information visit www.ethypharm.com and follow us on LinkedIn Media contact Yvonne Moeller | Director Communications Europe Aurora Europe GmbH | Wilmersdorfer Straße 98/99 | 10629 Berlin - Germany M +49 (0) 176 18000 560 | T +49 (0)30 9832 1601 0 yvonne.moeller@auroramedicine.com | www.auroramedicine.com Avril Ponnelle | Group Communication Manager Ethypharm | 194 Bureaux de la Colline | 92213 Saint-Cloud Cedex - France M +33 6 3051 2527 | T +33 1 4112 1720 presse@ethypharm.com | www.ethypharm.com

Lire la suite

Ethypharm Group

Ethypharm is a European pharmaceutical company focused on two areas: the Central Nervous System and Hospital injectables. Ethypharm markets its drugs directly in Europe and China, and with partners in North America and the Middle East where its drugs are in high demand. The Group employs 1,750 people, mainly in Europe and China. Ethypharm works closely with authorities and healthcare professionals to ensure the appropriate use of and access to its medicines, by as many people as possible.

Presse Ethypharm

Press

Contact
23/04/2021

Ethypharm establishes direct presence in Italy

Ethypharm announces today that it now has a fully established affiliate to operate directly in Italy, the third largest pharmaceutical market in Europe. Under the leadership of Bruno Rago, Ethypharm Italy will reinforce the group's commercial footprint in Europe, notably in its core therapeutic area of the Central Nervous System. Founded in 1977 in France, Ethypharm is a specialty pharmaceutical company with solid roots in Europe and China. After its establishment in the United Kingdom and Germany in 2015, the addition of a direct presence in Italy is a major milestone to strengthen the group’s commercial platform in Europe. Ethypharm Italy Srl is headquartered in Padova and will serve both the hospital and retail pharmacy channels.  Ethypharm Italy does not start from scratch but builds on solid foundations. Ethypharm already had several of its products distributed in Italy, notably in the Central Nervous System area. The team in place reflects the human values of Ethypharm: entrepreneurial spirit, strong pharmaceutical expertise and unique commitment to improve the life of patients. “Bruno Rago is a senior pharma and biotech industry executive. With him, Ethypharm benefits from over 20 years of experience. Bruno has a passion for building and establishing pharmaceutical affiliates in Italy and Europe. We know that under his leadership, Ethypharm Italy has a bright future” says Jean Monin, Chief Commercial Operations Officer of Ethypharm. Italy is one of the world's leading pharmaceutical markets. In 2019, the pharmaceutical market in Italy was estimated at 30 billion euros1]. Within it, the off-patent CNS market was worth 3,4 billlion euros. “I am happy to take this new challenge and I am confident as I already know the potential and the value of Ethypharm’s strategy and portfolio. I also know that we are able to relieve patients in pathologies such as epilepsy, pain and depression where healthcare professionnals and patients have needs” explains Bruno Rago, general manager of Ethypharm Italy.  About Ethypharm Ethypharm is a European pharmaceutical company focused on two therapeutic areas: the Central Nervous System and Critical Care. Ethypharm markets its drugs directly in Europe and China, and with partners in North America and the Middle East where its drugs are in high demand. The Group employs more than 1,500 people, mainly in Europe and China. Ethypharm works closely with authorities and healthcare professionals to ensure the appropriate use of and access to its medicines, by as many people as possible. For more information visit www.ethypharm.com and follow us on LinkedIn Media Contacts Ethypharm: Mai Tran, presse@ethypharm.com, + 33 (0)6 64 74 70 80

06/04/2021

Ethypharm ready to bring to patients world-leading digital therapies for depression and addiction

Saint-Cloud, France – April 6th, 2021 – Ethypharm announces today that it has acquired exclusive rights for two CE-marked digital therapies, deprexis® and vorvida®, developed by GAIA AG (GAIA), a global leader in digital therapeutics. With these innovative clinically-proven digital therapies, Ethypharm strengthens its product offering to support patients and healthcare providers in its core area of the Central Nervous System (CNS) where there are significant unmet needs. 30 million European individuals suffer from depression. The burden of mental disorders is growing, with significant impacts on health and major social and economic consequences. The ongoing COVID-19 pandemic is leading to an increase in cases of depression and alcohol use disorders (AUD). In parallel, to address the pandemic, digital health technologies have been adopted at a fast pace to help maintain an appropriate care of patients. In this context and using its expertise in CNS, and more specifically in pain, addiction and depression, Ethypharm has identified that, beyond conventional medicines, innovative and reliable therapeutic solutions could offer new alternatives to treat patients and support healthcare professionals currently facing unmet needs. deprexis® is a web-based digital therapy medical device to help patients manage their symptoms of depression and one of the world’s most researched digital treatments. vorvida® is helping to reduce the risks and damages caused by problematic alcohol consumption. This digital therapy has proven clinical efficacy in the treatment of bothersome or harmful alcohol consumption including diagnosed alcohol use disorder (AUD). Ethypharm acquires exclusive rights for deprexis® in 4 European countries: France, the United Kingdom, Italy and Spain. vorvida® is first licenced for France, with rights to future extensions in other European countries. Under the terms of the agreement with GAIA, Ethypharm will ensure the marketing and sales of these two digital therapeutics within their licenced territories. Digital therapeutics will be a key lever to Ethypharm’s growth. According to Market Data Forecast, the European digital therapeutics market was valued at US$ 612 million in 2020 and is forecasted to grow at a compounded annual growth rate of 21.4% between 2021 to 2026. “Mental disorders are a worldwide major burden on people, society and the economy. With COVID-19 and associated growing concerns on mental health, we wanted to provide innovative treatment options for patients and their physicians. These disruptive digital therapies have proven their efficacy and therefore, fit extremely well with Ethypharm’s ambition to improve people’s lives. The partnership with GAIA, a pioneer in digital health, is the illustration of the ability of Ethypharm to listen to unmet needs and either to develop or find the optimal partner to answer them.” said Bertrand Deluard, CEO of Ethypharm. "After 20 years of R&D in this field, it is great to see that healthcare systems all over Europe start realising the enormous potential that scientifically proven DTx products have to offer. We are therefore more than happy that Ethypharm will bring two of our products to key European markets, helping to reduce the enormous medical, psychological and economical burden these diseases create. " Dr. Mario Weiss, CEO and Founder of GAIA, commented. About Ethypharm Ethypharm is a European pharmaceutical company focused on two therapeutic areas: the Central Nervous System and Critical Care. Ethypharm markets its drugs directly in Europe and China, and with partners in North America and the Middle East where its drugs are in high demand. The Group employs more than 1,500 people, mainly in Europe and China. Ethypharm works closely with authorities and healthcare professionals to ensure the appropriate use of and access to its medicines, by as many people as possible. For more information visit www.ethypharm.com and follow us on LinkedIn About GAIA GAIA is a global leader in digital therapeutics (DTx), launching its first product successfully in 2001. With its stringent focus on research and development of evidence based, fully-automated online interventions the company continuously shifts benchmarks when it comes to effect sizes and safety profiles for digital therapeutics in neuroscience, immunology, oncology, or behavioral health. With more than 250 experts in the field of Medicine, Psychology, Behavioral Medicine, Software Engineering as well as Regulatory and Market Access, GAIA is one of the most experienced and largest global players in the development of next generation digital solutions to support and treat patients with a broad variety of medical conditions. For more information about GAIA please visit www.gaia-group.com. You can also follow GAIA on Twitter, @GAIA_COM, and LinkedIn Media Contacts • Ethypharm: Mai Tran, presse@ethypharm.com, + 33 (0)6 64 74 70 80 • GAIA: Johann Meyer-Christian, johann.meyerchristian@gaia-group.com, +41 79 614 46 44

16/03/2021

Ethypharm partners with Clever Leaves for medical cannabis products in Germany

St-Cloud, France – March 17th, 2021 – Ethypharm has signed an exclusive licence agreement with Clever Leaves for the sale of medical cannabis extracts in Germany, the most important European market for medical cannabis. For Ethypharm, this is a further step to become a leading and trusted provider of medical cannabis products in Europe. This agreement expands the Ethypharm Group’s offering in its core therapeutic area of the Central Nervous System and confirms its commitment to support patients suffering with chronic pain. “Working with physicians and pharmacists to improve people’s lives is one of Ethypharm’s daily ambitions. Today, providing medical cannabis will answer a clear unmet medical need for patients who are not relieved with current treatments. Partnerships are part of Ethypharm’s DNA. We always look for the optimal partner in any country or region of the world. This collaboration on medical cannabis with Clever Leaves is a good example of how Ethypharm has developed new ways to provide patients with the medical treatment care they need.” said Bertrand Deluard, CEO of Ethypharm. Clever Leaves, a well recognised cannabis company, will manufacture and supply EU-GMP certified medical cannabis extracts sourced from their facilities in Colombia. The finished products will be marketed and distributed as an Ethypharm branded product portfolio in Germany by its local subsidiary in the 2nd half of 2021. The portfolio include high-CBD, high-THC, and balanced CBD-THC formulations aiming at the symptomatic treatment of neurological diseases as well as chronic pain in palliative settings. “This partnership with Ethypharm, an established European pharmaceutical company, advances our goal of providing market-leading medical cannabis products to patients. Clever Leaves’ focus on high-quality EU-GMP production and international supply chain has positioned us to develop, produce and ship products to endmarkets that will have significant impact on patients’ treatments”, said Kyle Detwiler, CEO of Clever Leaves. Germany is the second European market after France where the Ethypharm Group offers medical cannabis. Last January, Ethypharm was selected by the French health agency (National Agency for the Safety of Medicines and Health Products - ANSM) to provide medical cannabis products for the first ever French medical cannabis pilot program. About the Ethypharm Group Ethypharm is a European pharmaceutical company focused on two therapeutic areas: the Central Nervous System and Critical Care. Ethypharm markets its drugs directly in Europe and China, and with partners in North America and the Middle East where its drugs are in high demand. The Group employs more than 1,500 people, mainly in Europe and China. Ethypharm works closely with authorities and healthcare professionals to ensure the appropriate use of and access to its medicines, by as many people as possible. For more information visit www.ethypharm.com and follow us on LinkedIn Media Contacts Ethypharm Corporate o Avril Ponnelle, presse@ethypharm.com, + 33 (0)1 41 12 17 20 Germany o Markus Gladbach, presse@thecommsduo.com, +49 157 71 44 60 98 o Christine Vogl-Kordick, presse@thecommsduo.com, +49 172 86 50 982

26/01/2021

Aurora Europe and Ethypharm collaborate to bring Medical Cannabis to French patients

Aurora Europe and Ethypharm selected to supply medical cannabis in the first ever French medical cannabis pilot program two-year program scheduled to commence by 31 March 2021 Berlin, Germany and St-Cloud, France, 26 January 2021 – Aurora Europe and the Ethypharm Group announce that they have reached a first important milestone in their collaboration agreement aimed at granting access to high-quality and trustworthy medical cannabis produced under European Good Manufacturing Practices (EU GMP) standard to patients and healthcare professionals in France. They are amongst the six producer and distributor tandems selected by the French health agency (National Agency for the Safety of Medicines and Health Products ANSM]) to provide medical cannabis products in the soon-to-start French pilot program. In a decree dated 7 October 2020, French authorities set the framework for a two-year pilot program of medical cannabis in France planned to start by 31 March 2021 and the French health agency ANSM was charged with running a tender process to select the medical cannabis products to be supplied in this program. Aurora Europe and the Ethypharm Group are happy to announce that they have been selected as the primary supplier for three lots out of nine awarded, which are: Aurora 20/1 (FR) (high-THC dried flowers), Aurora 8/8 (FR) (THC:CBD balanced dried flowers) and Aurora 1/12 (FR) (high-CBD dried flowers). With that the entire supply of dried flower medical cannabis to French patients during the pilot program will be ensured by this collaboration. “This is an important milestone and a great success for Aurora in our effort to improve the status and accessibility of medical cannabis in Europe,” said Dr. Axel GILLE, President of Aurora Europe. “Providing high-quality medical cannabis dried flower to the French pilot program is the first and very important step towards providing better access and will support the destigmatization of medical cannabis in France. If successful, this pilot program could lead to a regulated market for medical cannabis, which would be one of the largest in Europe.” Aurora has a proven track record of supporting the advancement of international medical cannabis markets alongside government bodies and with a deep commitment to compliance. This practice has led to successful leadership in expanding markets including Germany, Denmark, Poland and more recently Israel. “We are very proud to be part of the solution for patients seeking medical cannabis treatment. With our deep expertise in disorders of the Central Nervous System and in highly regulated medicines, we are well prepared to enter this new segment,” explained Bertrand DELUARD, President and CEO of Ethypharm. “Collaboration and partnerships are part of Ethypharm’s DNA. Combining our skills with Aurora’s pharmaceutical-quality cannabis products is in our view the right approach to build trust and confidence in medical cannabis for the long term.” Aurora and Ethypharm signed a collaboration agreement to serve the French pilot program in October 2020 leveraging both parties' expertise. Under the terms of the exclusive partnership, Aurora will supply European Good Manufacturing Practices (EU GMP) certified medical cannabis sourced directly from Aurora’s largest greenhouse production on European soil, Aurora Nordic, in Odense, Denmark, as well as manufacturing and logistics support. Laboratoires Ethypharm will be responsible for distribution and pharmacovigilance activities in France. About Aurora Europe Aurora Europe, headquartered in Berlin, Germany, is a subsidiary of Aurora Cannabis Inc., a global leader in the cannabis industry serving both medical and consumer markets and dedicated to helping people improve their lives. Aurora Europe supplies high-quality medical cannabis products to patients throughout Europe. In 2015, Aurora entered the German market and today operates one of the largest authorised importers and distributors of medical cannabis in Europe. Aurora’s internal network of EU GMP facilities continues to bring high-quality, premium medical cannabis to patients worldwide. For more information visit www.auroramedicine.com and follow us on LinkedIn. About the Ethypharm Group Ethypharm is a European pharmaceutical company focused on two therapeutic areas: the Central Nervous System and Critical Care. Ethypharm markets its drugs directly in Europe and China, and with partners in North America and the Middle East where its drugs are in high demand. The Group employs more than 1,500 people, mainly in Europe and China. Ethypharm works closely with authorities and healthcare professionals to ensure the appropriate use of and access to its medicines, by as many people as possible. For more information visit www.ethypharm.com and follow us on LinkedIn Media contact Yvonne Moeller | Director Communications Europe Aurora Europe GmbH | Wilmersdorfer Straße 98/99 | 10629 Berlin - Germany M +49 (0) 176 18000 560 | T +49 (0)30 9832 1601 0 yvonne.moeller@auroramedicine.com | www.auroramedicine.com Avril Ponnelle | Group Communication Manager Ethypharm | 194 Bureaux de la Colline | 92213 Saint-Cloud Cedex - France M +33 6 3051 2527 | T +33 1 4112 1720 presse@ethypharm.com | www.ethypharm.com

19/01/2021

ORPHELIA Pharma and Ethypharm sign a licensing agreement for the development and marketing of Kigabeq® in China

Saint-Cloud and Paris – January 19, 2021 - Ethypharm and ORPHELIA Pharma announce today the signature of an exclusive agreement for the development, registration and marketing in the People's Republic of China of Kigabeq® (vigabatrin) indicated for the first-line treatment of infantile spasms (West syndrome). Kigabeq®, the first paediatric form of vigabatrin developed by ORPHELIA Pharma, is approved and marketed in Europe, where this medicine, intended exclusively for children, has been granted a Paediatric Use Marketing Authorisation (PUMA). Kigabeq® is indicated for the first-line treatment of infantile spasms (West’s syndrome), a severe epileptic encephalopathy in infants. There is a significant unmet medical need in China for patients suffering from this rare and devastating form of epilepsy. By entering into this agreement, Ethypharm and ORPHELIA Pharma are committed to providing appropriate treatment for Chinese children suffering from this rare disease. As part of this agreement, ORPHELIA Pharma grants Ethypharm exclusive rights to Kigabeq® in the People's Republic of China. After registration, Ethypharm will be responsible for the distribution and sale of Kigabeq® in China. "Our objective is to make Kigabeq® available in many territories. After Europe and China, new agreements will be signed to enable the marketing of this formulation of vigabatrin, which is particularly suitable for children," comments Hugues BIENAYMÉ, founder and Managing Director of ORPHELIA Phama. "We are very pleased to establish this partnership with ORPHELIA Pharma. This collaboration brings an effective solution to young Chinese patients. The upcoming commercialisation of Kigabeq® is fully in line with our strategy to strengthen our rare disease franchise in China" said Bertrand DELUARD, President and CEO of Ethypharm. Through this partnership, Ethypharm is strengthening its ambition to become a key player in the field of rare diseases in China. Operating successfully for more than 20 years in an ever-changing Chinese environment, Ethypharm has a fully integrated subsidiary located in Shanghai. "Our subsidiary is a partner of choice for companies wishing to make their existing internationally-marketed orphan drugs or drugs for rare diseases available to Chinese patients," says François LIOT, General manager of Shanghai Ethypharm. "I am delighted to sign this agreement with Ethypharm, which is based on the value of Kigabeq® in paediatrics. Thanks to the in-depth knowledge that the Ethypharm Group is developing in China, we are very confident that chinese children suffering from infantile spasms will have access to Kigabeq® as quickly as possible," adds Gilles ALBERICI, Chairman of ORPHELIA Pharma. About Kigabeq® Kigabeq® is the first paediatric formulation of vigabatrin, an essential anti-epileptic drug. Kigabeq® is available in 100 mg and 500 mg soluble and scored tablets for oral or (naso)gastric administration and is indicated for the first-line treatment of childhood spasms (West’s syndrome), a severe epileptic encephalopathy in infants. Kigabeq® has been developed exclusively for children and has been granted Paediatric Use Marketing Authorisation (PUMA). About infantile spasms West’s syndrome, or infantile spasms, is a severe epileptic encephalopathy of the infant that combines epileptic spasms, a psychomotor deterioration and an hypsarrhythmic electroencephalogram tracing. It is a rare disease, with an estimated incidence of 5 per 10,000 births. It can occur in infants with previously normal development or with a pre-existing delay; in all cases, infantile spasms have a strong impact on the psychomotor development. Pharmacological treatment must be started quickly to allow the spasms to stop and improve the prognosis. About the Ethypharm Group Ethypharm is a European pharmaceutical company focused on two therapeutic areas: the Central Nervous System and Critical Care. Ethypharm markets its drugs directly in Europe and China, and with partners in North America and the Middle East where its drugs are in high demand. The Group employs more than 1,500 people, mainly in Europe and China. Ethypharm works closely with authorities and healthcare professionals to ensure the appropriate use of and access to its medicines, by as many people as possible. About ORPHELIA Pharma ORPHELIA Pharma is a biopharmaceutical company based in Paris and Lyon that develops and markets drugs for the treatment of paediatric and rare diseases. Our mission is to provide patients with essential hospital products in the fields of epilepsy and oncology with formulations adapted to the paediatric population. Our first product, Kigabeq®, received European marketing authorisation in September 2018 and is being launched in several countries. Our second product, Ivozall®, obtained European marketing authorisation in November 2019 for the treatment of acute lymphoblastic leukaemia. ORPHELIA Pharma conducts research projects through academic and industrial collaborations. For more information, please visit www.orphelia-pharma.eu Press contact Avril PONNELLE / presse@ethypharm.com / + 33 (0)1 41 12 17 20 Séverine MARTIN / orphelia@orphelia-pharma.eu / +33 (0)1 42 77 08 18

09/11/2020

Ethypharm and CTRS sign a partnership agreement to register and commercialise Orphacol® in China

St-Cloud and Boulogne-Billancourt, France - November 10, 2020 – Ethypharm and Laboratoires CTRS announced today that they have entered into an exclusive agreement for the registration and commercialisation of the orphan medicine Orphacol® indicated for the treatment of patients with rare inborn errors in primary bile acid synthesis. Under the agreement, CTRS has granted Ethypharm the exclusive rights for Orphacol® in the People’s Republic of China. Ethypharm and CTRS will jointly fund and undertake all the necessary requirements to bring Orphacol® to market in China. After registration, Ethypharm will be responsible for the distribution, marketing and sale of the products in that territory. Orphacol® (cholic acid) is already approved in Europe where it benefits from an orphan drug status. It is indicated for two rare inborn errors of primary bile acid synthesis. The innovation brought by Orphacol® to patients has been highly recognised by the scientific community. Successfully operating in the fast-changing Chinese environment for over 20 years, Ethypharm has a fully integrated subsidiary located in Shanghai. This affiliate is a partner of choice for companies that wish to bring to Chinese patients their already internationally marketed rare disease or orphan medicines. “This partnership with CTRS represents an important milestone for Ethypharm in the construction of our rare disease franchise in China. Orphacol® is a highly innovative life-saving product which fulfils unmet medical need. We are proud to participate in its success and make this medicine available to the affected patients in China” said Bertrand DELUARD – President & CEO of Ethypharm. “We are very pleased to enter into this exclusive license agreement with Ethypharm based on its deep insight and unique capabilities in China, which make us highly confident that the Chinese patients suffering of bile acid synthesis disorders will quickly have access to Orphacol®” added Antoine FERRY, CEO of Laboratoires CTRS. About the Ethypharm Group Ethypharm is a European pharmaceutical company focused on two therapeutic areas: The Central Nervous System and Critical Care. Ethypharm markets its drugs directly in Europe and China, and with partners in North America and the Middle East where its drugs are in high demand. The Group employs more than 1,500 people, mainly in Europe and China. Ethypharm works closely with authorities and healthcare professionals to ensure the appropriate use of and access to its medicines, by as many people as possible. For more information on Ethypharm, visit http://www.ethypharm.com and follow us on LinkedIn. in the People’s Republic of China for the treatment of patients with rare inborn errors in primary bile acid synthesis. About Laboratoires CTRS Laboratoires CTRS is a pharmaceutical company based in France with a strong and growing international presence in orphan and ultra-orphan disorders. CTRS has successfully established public-private partnerships and collaborations with leading research groups with predominant focus on genetic disorders and cancer. CTRS has a staff of 20+ employees and a network of long-term contractors/commercial partners around the world. For more information about us, please go to www.ctrs.fr and follow us on LinkedIn. About Orphacol® Orphacol® (cholic acid) is an approved treatment for inborn errors in primary bile acid synthesis due to 3β-hydroxy-Δ5-C27-steroid oxidoreductase deficiency or Δ4-3-oxosteroid-5β-reductase deficiency. Orphacol® has a centralised marketing authorisation, valid for all markets of the EU, Norway and Iceland. The product also enjoys orphan drug market exclusivity. Orphacol® is a life-saving treatment which has obtained national and international awards such as “Prix Galien” and “International Prix Galien”. The product also obtained the highest recognition from Prescrire (an independent medical journal in France). Press contact Avril PONNELLE /presse@ethypharm.com/+ 33 (0)1 41 12 17 20 Laetitia EVAIN / levain@ctrs.fr /+33 (0)1 41 22 09 70 

29/01/2020

Jean MONIN appointed Chief Commercial Operations Officer (CCOO) of the Ethypharm Group

St-Cloud, France – 29 January 2019 – The Ethypharm Group is delighted to announce the appointment of Jean MONIN as Group CCOO. This appointment took effect on 21 January 2019. He joined the Group’s Executive Committee. Jean MONIN, 52, is a Pharmacist and a graduate of the ESSEC Business School. He has a solid background in the Pharmaceutical Industry, with over 25 years’ experience including 12 years abroad. He started his career as a Medical Information Officer with Rhône Poulenc in Australia, then developed his managerial skills over time with roles of increasing complexity, mainly in the Marketing and Sales divisions of Aventis France and Sanofi Spain, before being appointed in 2007 as General Manager of Sanofi in Norway, and subsequently in Belgium & Luxembourg. In 2010 he left Europe to take up the position of General Manager of Sanofi’s Australia & New Zealand subsidiary. In 2012 Jean moved into “biotechs”. He joined Amgen and became the head of the Group’s largest European subsidiary as Vice-President General Manager of Amgen France. Bertrand Deluard – CEO of Group Ethypharm – comments: “Jean’s leadership skills, international experience and market awareness will greatly help Ethypharm achieve its ambitious development goals. His expertise will be a key asset in guaranteeing high performance among our commercial operations performance in Europe and around the world. In terms of transformation, Jean will be eager to help implement the Group’s strategy, develop our partnerships, strengthen our growth platforms, and support the successful launching of our future products in the areas of pain, addiction and critical care. “Growth is fundamental if we are to continue delivering essential medicines to our patients. I am very proud to contribute to Ethypharm’s commercial success, as talented people throughout the company maintain an impressive track record of transforming their business to deliver this growth” adds Jean MONIN - Chief Commercial Operations Officer (CCOO) of the Ethypharm Group. About Ethypharm Ethypharm is a European-based specialty pharmaceutical company with global reach and a committed player in the treatment of pain and addiction. Ethypharm also develops and markets complex generics and essential medicines that help reduce healthcare costs, particularly in the field of emergency care and oncology. The Company employs 1400 people mainly in Europe, and its drugs are marketed in more than 80 countries. Our ambition is to become the European leader for the treatment of pain and addiction, and to help patients around the world gain access to high quality, essential and affordable medicines. To learn more about the Ethypharm Group, visit our website: www.ethypharm.com Press contact – Avril PONNELLE /presse@ethypharm.com/+ 33 (0) 1 41 12 17 20